The mer-trichloro dimethylsulphoxide-S-(1,10-phenanthroline) ruthenium (III) ([Ru(phen) 
Metal-based compounds constitute a discrete class of chemotherapeutics widely used as anticancer and antiviral agents. Most established antitumor metal-based drugs are cisplatin and its analogues, such as carboplatin and oxaliplatin. Cisplatin is an anticancer agent being used for the treatment of testicular, ovarian, head, neck and germ cell tumors (Rosenberg B,1985 and Bertino JR et al., 1997). However, the optimal use of this drug is limited due to its dose limiting nephrotoxicity. The new platinum compounds like carboplatin and oxaliplatin are found to possess comparatively very narrow therapeutic index, and also it has limited clinical utility due to drug resistance and side effects (Dabholkar M et al.,1996 and Shimada H et al.,1993) . Hence it is necessary to look for more effective and less toxic other metal-based anticancer agents.
Ruthenium complexes have attracted much interest as alternative drug to cisplatin in cancer chemotherapy. Ruthenium complexes have similar ligand exchange kinetics as platinum (II) complexes and exist in different oxidation states under different physiological conditions(Jakupec M A et al., Schluga P et al., 2006) . Many reviews that illustrate the unique DNA binding modes and antitumor effects have been reported (Kostova I 2006) . Ruthenium complexes are presently receiving great attention in the fields of biological, pharmaceutical and medicinal chemistry as anti-tumor agents. Ruthenium compounds show low systematic toxicity and appear to penetrate reasonably well within the tumor cells, binding effectively to DNA and proteins and presenting in some cases selective anti-metastatic properties (Brabec V and Novakova O, 2006 ) However, it is essential to design superior drugs in terms of effectiveness compared to cisplatin and other metal drugs (Rosenberg B et al.,1965) . The 1-10 phenanthroline (phen) ligand has been found in many metalbased anticancer agents (Clarke MJ . The ligands like isatin, thio semicarbazones, and chloro-fluoro-phenyl are also found in some Ru(II) complexes and the cytotoxic activity both in vivo and in vitro studies of these complexes are promising (Karki SS et al., 2007) . Similarly, NAMI emerges out as anti-metastatic agent, but only small fraction of the compound can reach the tumour target (Galanski M 
Crystal structure determination:
Single crystal X-ray diffraction data was obtained at 100 K with Brunker smart AXS diffractometer with graphite-monochromatised Mo-K radiation by - scans. We used full matrix least square on F 2 . The molecular graphic structure was analyzed by ORTEP plot program. The structure was refined by using SHELXL-97, other materials were prepared by wingx publication routine (Figure 1) Structure solution and refinement: The structure was solved by SHELXS97 (Sheldrick GM 1997), and refinement was carried out by full-matrix least square on F 2 using the same program SHELXL97. All non-H atoms are refined with anisotropic temperature factors and the hydrogen atoms were positioned from the different synthesis map with isotropic temperature factors of Uiso(H) = 1.2 Uiso (C) for CH and 0.114 Uiso(C) for CH 3 .401 refined parameters, final R1= 0.0347, wR2 = 0.0892 for 8001 reflections with I > 2σI, and final R1= 0.0478, wR2= 0.0994 for all data, with largest peak difference and hole of 0.780/-0.726 e Å -3 in the vicinity of the Cl 3 and O 1 atom. The structural data has been deposited to Cambridge Crystallographic Data Center (CCDC 889313).
Spectroscopic studies on DNA binding:
The spectroscopic, electrochemical and electrophoresis studies of this Ru complex with Calf Thymus DNA (CT-DNA) have been carried out. We observed distinct spectral shift after mixing the complex with CT-DNA. It might be due to CT-DNA binding by this complex.
UV-Visible Absorption Titration:
The UV-visible absorption spectra of [Ru(phen)(DMSO)Cl 3 ] complex in presence of CT-DNA has been performed (Figure 2) . 
Electrochemistry:
Cyclic voltammetric study for [Ru(phen)(DMSO)Cl 3 ] complex was carried out in DMSO solution(0.005 M) containing 0.1 M TBAP as supporting electrolyte using Ag/Ag + as reference electrode, and a glassy carbon electrode was used as working electrode. Inert environment was maintained by passing N 2 gas through the solution to remove oxygen. The cyclic voltamogram shows distinct oxidation and reduction peaks of a reversible electron transfer couple at scan rate 100 mVs -1 . The shift of redox potential (E 1/2 ) from 222 mV to 256 mV on addition of CT-DNA was observed (Figure 4 ).
Electrophoresis experiment:
The binding of trichlorodimethylsulphoxide-S-(1,10-phenanthroline) ruthenium (III) complex with CT-DNA was further supported by electrophoresis experiment. The solution of CT-DNA was prepared in tris-HCl buffer at pH 7.6. The binding of complex with CT-DNA was monitored by preparing solutions of the complex having three different concentrations, 6 mM, 3 mM and 2 mM with CT-DNA, which was incubated for 24 hours at 37º C before running Gel Electrophoresis. The three solutions were placed at three different lanes, 1, 2 and 3 in the gel along with free CT-DNA (5 mM), which was kept at lane C. The composition of base pairs in the CT-DNA used in this experiment was 42 mole for GC, 58 mole for AT in 100 mole. The samples were run from -ve to +ve potential for 3 hours at different voltages (half an hour at 50 V, 1 hour at 60 V, half an hour at 70 V and 1 hour at 80 V) on a 1% agarose gel prepared in tris-borate EDTA. After photographed the gel under UV light, it appears that lane C moves faster than lane 1, 2 and 3 and the brightness decreases from lane C lane 1, 2 and 3 ( Figure 5 ).
Biological studies of trichlorodimethylsulphoxide-S-(1,10-phenanthroline) ruthenium (III) complex: Effect of different concentrations of trichloro dimethylsulphoxide-S-(1,10-phenanthroline) ruthenium (III) complex on mice bearing Dalton's lymphoma:
C 3 H/He strain of mice both male and female, 8-10 weeks old and weighing 20-22g was used in all sets of experiments. Animals were kept in polypropylene cages and were fed on a commercial diet (Goldmohar, Lipton, India) and tap water ad libitum. Mice were kept under standard condition (especially pathogen free, temperature ranging from 22-23 0 C and relative humidity 65-70%. Transplantable ascites Dalton's lymphoma was obtained from Chittaranjan National Cancer Research Centre, Kolkata, India and maintained in the laboratory by regular serial transplantations by injecting 2x10 7 cells/mice in PBS after a regular interval of 10 days. Ruthenium compound, trichlorodimethylesulphoxide-S-(1,10-phenanthroline) ruthenium (III) was prepared in the laboratory as mentioned. All other chemicals were purchased from Hi-media, Mumbai, India and were of analytical grade.
Control and experimental animals were selected randomly and divided into groups of 10 mice each according to randomized block design. Each animal was transplanted with 3x10 6 cells/mice. After 4 days of post-tumor transplantation, the experimental mice were treated with single i.p. injection of different concentrations of trichloro dimethylsulphoxide-S-(1,10-phenanthroline) ruthenium (III) dissolved in Phosphate buffered saline (PBS) (pH 7.4). Control animals were injected with equal amount of PBS. In each group % Survival, increase in the mean survival time of tumor bearing mice and tumor free survivors were observed.
Effect of trichlorodimethylsulphoxide-S-(1,10-phenanthroline) ruthenium (III) complex on the survival of Dalton's lymphoma cells in vivo:
Dalton's lymphoma cells were isolated from the peritoneal cavity of tumor bearing mice (control and treated with different concentrations of this Ru complex). 2-3 ml of sterile phosphate buffered saline (PBS) was injected into the peritoneal cavity and the fluid containing the tumor cells was withdrawn, and collected in sterile petridishes for incubation at 37 0 C for 2 hours. The cells of macrophage lineage adhered to the bottom of petridishes to form a confluent monolayer. The non-adherent population of lymphoma cells was gently aspirated out and washed repeatedly with PBS. The viability was tested by tryphan blue exclusion test.
Effect of trichlorodimethylsulphoxide-S-(1,10-phenanthroline) ruthenium (III) on the survival of Dalton's lymphoma cells in vitro:
For cytotoxicity assay in vitro, Dalton's lymphoma cells were plated at high density (8x10 7 cells/dish) at time 0 in DMEM containing fetal calf serum, 10 mM NaHCO 3 , 0.3% glutamine and different concentrations of Ru complex for a fixed treatment duration of 1 hour. Control dishes were treated with equal amount of PBS used as a solvent for trichlorodimethyl sulphoxide -S-(1,10-phenanthroline) ruthenium(III). At the end of drug treatment, cells were harvested and washed with PBS, suspended again in ADM with DFCS and incubated for 72 hours at 37 0 C. After incubation, cells were trypsinized and viable cells were counted by tryphan blue exclusion test.
III.
Results and Discussion:
The geometry around the ruthenium atom of [Ru(phen)(DMSO)Cl 3 ] is found to be octahedral with a phen ligand occupying two coordination sites while the other coordination sites are occupied by one DMSO and three chlorine atoms. The compound was prepared by refluxing the RuCl 3 .3H 2 O and phen in solvent mixture of ethanol and water, and subsequent addition of DMSO. Initially, the two Cl atoms might be replaced by phen ligand, and then DMSO molecule reacts with Ru(phen)Cl 4 .2H 2 O to replace the inner Cl atom to give [Ru(phen)(DMSO)Cl 3 ]. The crystalline compound so obtained was analyzed by XRD studies and the ORTEP structure is shown in Figure 1 . The fluorescence spectra of the complex is found different from the spectra taken after mixing with CT DNA (Figure 3) . In addition to the original apex at 324 nm of the complex, a new peak was observed at 445 nm, which becomes more intense on increasing the concentrations of CT-DNA from 0.59 X10 Electrophoresis of CT-DNA (5 mM) revealed a more intense band but when a higher concentrations of CT-DNA (6 mM) was mixed with same amount of Ru complex a very weak band was observed ( Figure 5) . This suggests the formation of DNA adduct with Ru complex. Further, as the concentration of CT-DNA was increased from 2-6 mM and mixed with same amount of Ru complex, the sharpness of DNA band was found to decrease indicating direct correlation between the amounts of DNA and adduct formation.
As we know that the metallic drugs, cisplatin is an important class of chemotherapeutic agent widely used in cancer chemotherapy, but its clinical use is limited due to nephrotoxicity (Kim YK et al., 1995 and Wolfgang GHI, et al., 1994) . Among the transition metal compounds, Ruthenium appears to be a likely candidate in near future even though its chemistry differs from that of platinum. The most significant differences are its octahedral geometry and greater propensity to undergo redox reactions. The hypoxic environment of many tumors may favor the reduction of ruthenium (III) compounds to ruthenium (II) species (Pegg D G et al., 1994 and Clarke MJ et al.,1988). The hydrophobicity of phenanthroline ligand is responsible for DNA binding ability and for possible anticancer activity of this complex (Chen T et al., 2012) .
In the present studies a newly synthesized ruthenium compound trichlorodimethylsulphoxide-S-(1,10-phenanthroline) ruthenium(III) was tested against murine's Dalton's lymphoma. Percentage survival of mice bearing tumor after treatment with this compound is shown in Figure 6 . A direct correlation was observed between the dose of compound administered and increase in the % survival of tumor bearing mice. All the control animals without any treatment failed to survive beyond 10 days post tumor transplantation. When the tumor bearing mice were treated with 20 mg/kg of compound, 100% of animals survived till day 18 post tumor transplant and the maximum survival period was found to be 28 days. When the dose of ruthenium compound was increased to 30 and 40 mg/kg, the maximum survival time increased to 30-32 days. When the concentration was further increased to 50 mg/kg the maximum survival period increased to 45 days (Figure 6 ). The viability of tumor cells was found to depend on the concentrations of ruthenium compound injected in mice. Increasing concentrations of Ruthenium compound had adverse effect on viability of tumor cells. Almost 90% of viability was observed with 10-20 mg/kg of compound. However, 30-40 mg/kg dose has shown 70-80% viable cells. The LC 50 was found to be 50 mg/kg (Figure 7) .
Present study has also shown the effects of Ruthenium compound at the cellular level through a study of its lethal activity in an in vitro system. Results obtained in the present study with Dalton's lymphoma cells are expressions of cell killing assay and not the growth inhibition assay. It was found that cytotoxicity of ruthenium compound depends upon its concentration in the culture media. Survival of Dalton's lymphoma cells treated in vitro with different concentrations of ruthenium complex for a fixed time duration of 1h is shown in Figure 8 . There exists an inverse linear correlation between the concentration of ruthenium in the medium and % survival of lymphoma cells. IC 50 of ruthenium was found to be 40 μg/ml (Figure 8) . .
Most of the investigations reporting ruthenium compounds as anti-tumor agents have been carried out as in vitro studies and only a few are in vivo studies. Ruthenium-DMSO complexes have been reported to increase the life span of tumor bearing mice in vivo (Pieper, T and Keppler, BK 1998) . These compounds are also effective against several murine models including a cisplatin resistant P 388 leukemia cell line. While a number of Ruthenium compounds have been tested, the prototype compound RAPTA-C has been reported to be most effective anti-cancer compound of this series and has been used extensively against a number of murine cell lines. Chatterjee S et al studied the effect of RAPTA-C induced apoptosis in EAC cells isolated from peritoneal cavity of tumor bearing mice and found that the apoptosis was dose dependent (Chatterjee S et al., 2008) . In the present studies, the effect of compound has also been found to be dose dependent. In a similar study, flow cytometry analysis of RAPTA-C induced cell cycle phase distribution of nuclear DNA has shown increased content of haploid DNA in RAPTA-C treated cells (Chatterjee S et al., 2008) . However, the DNA in S-phases decreased from 6.3 to 3.6 % suggesting that tumor suppressor gene P 53 is central to the induction of cell cycle arrest and apoptosis in response to DNA damage of cellular stage in human cells. Earlier it has been reported that ruthenium (III) compounds having significant cytotoxic properties are able to bind firmly to DNA and modify its structural conformation (Brabec V et al.,1995) . So the anticancer activity of the present compound may be related to its DNA binding ability.
IV.

Conclusion:
The synthesis of ruthenium complex, its CT-DNA binding and biological studies have been performed. The structure analyzed by single crystal XRD study shows six-coordinated octahedral geometry. The crystal structure is a representative complex, [Ru(phen)(DMSO)Cl 3 ], and the structural features are in accord with already reported ruthenium complexes. The CT-DNA binding of this complex is evidenced by various experimental techniques. On the basis of spectroscopic shift, the intrinsic binding constant (K b ) is found to be 2.77X10 4 M -1 . Based on the observed distinct shift of electrochemical E 1/2 and electrophoresis band shifts, the complex is expected to bind with CT-DNA. The hydrophobicity of the phen ligand may be responsible for DNA binding and possibly related to the anticancer activity of ruthenium complex. This compound acquires good antitumor property against Dalton's lymphoma both in vivo and in vitro. The compound exhibited dose dependent increase in the survival time of tumor bearing mice, however, no tumor free survivor was observed. From the biological studies in vivo, the highest dose of this complex is 50 mg/kg. Electrophoretic analysis of CT-DNA with the complex suggests the formation of DNA adduct, which might be responsible for the antitumor activity of this compound. Figure1 ORTEP molecular structure of the Ru(phen)(DMSO)Cl 3 complex. Selected distances/Å and bond angles/º Ru1-N1=2.082(2), Ru1-N2=2.088(2), Ru1-S1=2.320(4), Ru1-Cl1=2.336(2), Ru1-Cl2=2.347(1), Ru1-Cl3=2.346(1), S1-O1=1.393(4), S1-C13=1.784(4), S1-C14=1.770(4), N1-Ru1-N2=79.22(10), Cl1-Ru1-N2=84.94(7), Cl2-Ru1-N2=92.23 (7), Cl3-Ru1-N2=95.71(8), Cl1-Ru1-N1=87.48 (7), Cl2-Ru1-N1=87.31 (7), Cl3-Ru1-N1=174.89(4), Cl1-Ru1-Cl2=174.45(3), Cl3-Ru1-Cl1=92.79(3), Cl3-Ru1-Cl2=92.24(3), S1-Ru1-N1=97.92(6), S1-Ru1-Cl1=91.31(3), S1-Ru1-Cl2=91.26(3), S1-Ru1 Cl3=87.38(3), Ru1-S1-O1=119.40(1), O1-S1-C13=102.50(3), O1-S1-C14=111.60(3), C13-S1-C14=99.27(4). 
